Yoon Ji-Young, Koo Yu-Jin, Kim Mi-Jung, Kim Tae-Jin, Lim Kyung-Taek, Lee Ki-Heon
Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine, Seoul, Korea.
Obstet Gynecol Sci. 2014 Nov;57(6):484-91. doi: 10.5468/ogs.2014.57.6.484. Epub 2014 Nov 20.
To assess the effect of single-dose cisplatin intraperitoneally administered during cytoreductive surgery in advanced epithelial ovarian cancer.
Data from patients who underwent surgical management followed by intravenous (IV) chemotherapy for stage III epithelial ovarian cancer from 2003 to 2012 were retrospectively reviewed. Subjects were divided into intraperitoneal (IP) and no-intraperitoneal (NIP) groups according to the administration of IP cisplatin 100 mg during the staging surgery. Clinical results such as survival outcomes and chemotherapeutic toxicity were compared between the two groups.
Thirty-seven patients in the IP group and 26 in the NIP group were identified. There were no significant differences between the two groups in basic characteristics such as age, histology, and surgical procedures. After the surgery with or without IP chemotherapy, there was no difference in the rate of either hematologic or gastrointestinal toxicity or in the rate of incompletion of following IV chemotherapy. Tumor recurrence occurred in 67.6% (25 patients) of IP group and 57.7% (15 patients) of NIP group (P=0.423) during the mean follow-up period of 37 months. The 3-year disease free-survival rate was 39.9% in the IP group and 35.8% in the NIP group, and the relative risk of recurrence was 0.864 (95% confidence interval, 0.447-1.673; P=0.665) in the IP group as compared with the NIP group.
IP chemotherapy with single-dose cisplatin during cytoreductive surgery is safe and feasible with little chemotherapeutic toxicity in advanced epithelial ovarian cancer, but no distinct improvement in survival could be demonstrated in the present study.
评估在晚期上皮性卵巢癌肿瘤细胞减灭术中腹腔内注射单剂量顺铂的效果。
回顾性分析2003年至2012年间接受手术治疗并随后接受静脉化疗的III期上皮性卵巢癌患者的数据。根据分期手术期间是否腹腔内注射100mg顺铂，将患者分为腹腔内注射组（IP组）和非腹腔内注射组（NIP组）。比较两组的生存结果和化疗毒性等临床结果。
IP组有37例患者，NIP组有26例患者。两组在年龄、组织学和手术方式等基本特征方面无显著差异。在接受或未接受腹腔内化疗的手术后，血液学或胃肠道毒性发生率以及后续静脉化疗未完成率均无差异。在平均37个月的随访期内，IP组67.6%（25例患者）出现肿瘤复发，NIP组57.7%（15例患者）出现肿瘤复发（P = 0.423）。IP组的3年无病生存率为39.9%，NIP组为35.8%，与NIP组相比，IP组复发的相对风险为0.864（95%置信区间，0.447 - 1.673；P = 0.665）。
在晚期上皮性卵巢癌肿瘤细胞减灭术中腹腔内注射单剂量顺铂进行化疗是安全可行的，化疗毒性较小，但本研究未显示出生存率有明显改善。
